Giovanni Sorrenti

Giovanni Sorrenti

Auto-generated profile, based on publicly available information

Giovanni Sorrenti

Department of Otolaryngology Head and Neck Surgery, S. Orsola-Malpighi University Hospital, Bologna, Italy

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2014 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
Andrea De VitoAndrea De Vito
Andrea De Vito
MLMarina Carrasco Llatas
Marina Carrasco Llatas
AVAgnoletti Vanni
Agnoletti Vanni
MBMarcello Bosi
Marcello Bosi
ABAlberto Braghiroli
Alberto Braghiroli
CVClaudio Vicini
Claudio Vicini

22 August 2018 in Clinical Otolaryngology
Verified
Journal Article
Closed access
PDF file
Andrea De VitoAndrea De Vito
Andrea De Vito
MCMarina Carrasco-Llatas
Marina Carrasco-Llatas
MRMadeline J. Ravesloot
Madeline J. Ravesloot
BKBhik Kotecha
Bhik Kotecha
NVNico De Vries
Nico De Vries
CVClaudio Vicini
Claudio Vicini

10 July 2013 in The Laryngoscope
Verified
Journal Article
Open access
PDF file
GSGiovanni Sorrenti
Giovanni Sorrenti
OPOttavio Piccin
Ottavio Piccin
Click on the article title to read more.

22 January 2007 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
LGLuigi Gatta
Luigi Gatta
DVD. Vaira
D. Vaira
GSG. Sorrenti
G. Sorrenti
SZS. Zucchini
S. Zucchini
CSC. Sama
C. Sama
NVN. Vakil
N. Vakil
Summary: Background: Many investigators have proposed an association between gastro‐oesophageal reflux disease and laryngo‐pharyngeal symptoms, suggesting that medical or surgical therapy for reflux may be useful.Aim: To perform a meta‐analysis assessing the effectiveness of medical or surgical therapy for reflux disease in adult patients with laryngeal or pharyngeal symptoms presumed to be due to gastro‐oesophageal reflux disease.Methods: Randomized controlled trials comparing medical or surgical treatments for gastro‐oesophageal reflux disease against placebo were identified by searching MEDLINE (1966–September 2005), EMBASE (1974–September 2005), the CCRCT (until September 2005) and abstracts from gastroenterology and ENT meetings. The relative risks of reporting symptomatic improvement or resolution of symptoms was evaluated using a random‐effects model.Results: Five studies using high‐dose proton pump inhibitor as intervention met the inclusion criteria and were included in the meta‐analysis. No surgical studies met inclusion criteria. The pooled relative risk was 1.18 (95% confidence interval: 0.81–1.74). There was no heterogeneity between studies but evidence of significant publication bias. Sub‐group analysis performed evaluating Jadad scores and symptom type, did not change the relative risk.Conclusions: Therapy with a high‐dose proton pump inhibitor is no more effective than placebo in producing symptomatic improvement or resolution of laryngo‐pharyngeal symptoms. Further studies are necessary to identify the characteristics of patients that may respond to proton pump inhibitor therapy.

9 January 2018 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
MBMarcello Bosi
Marcello Bosi
Andrea De VitoAndrea De Vito
Andrea De Vito
BKBhik Kotecha
Bhik Kotecha
LVLuca Viglietta
Luca Viglietta
ABAlberto Braghiroli
Alberto Braghiroli
Venerino PolettiVenerino Poletti
Venerino Poletti

1 December 2006 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
GSGiovanni Sorrenti
Giovanni Sorrenti
OPOttavio Piccin
Ottavio Piccin
SMSusanna Mondini
Susanna Mondini
ACAlberto Rinaldi Ceroni
Alberto Rinaldi Ceroni